title: Urinary 11-dehydro thromboxane B₂ levels in type 2 diabetic patients before and during aspirin intake.
abstract: BACKGROUND
  Diabetic patients commonly present an increased risk for cardiovascular events, for which aspirin is the most frequently used medication for primary prevention. Urinary 11-dehydro thromboxane (11-dhTXB₂) concentrations assess the effect of aspirin on platelets and identify patients who are at risk of cardiovascular events. The present study investigated whether or not type 2 diabetic patients who took a daily dose of 100mg of aspirin had a significant reduction in urinary 11-dhTXB₂ concentrations and whether these results were associated with clinical and laboratory variables.
  
  
  METHODS
  Eighty-one type 2 diabetic patients were enrolled in the study. Laboratory tests included the determination of lipidic profile, glycated hemoglobin, platelets count, molecular analysis for both GPIIbIIIa and COX-1 polymorphisms, and urinary 11-dhTXB₂.
  
  
  RESULTS
  Patients' median value for urinary 11-dhTXB₂ before aspirin intake was 179 pg/mg of creatinine. After 15days taking aspirin, the patients presented median of 51 pg/mg of creatinine, thus revealing a significant difference between medians (p=0.00). A reduction of 95% in urinary 11-dhTXB₂ concentrations could only be identified in 4 patients (5%). A BMI of ≥ 26 presented a significant association with a reduction of urinary 11-dhTXB₂ concentrations (p=0.010), as shown by the multiple logistic regression model. Other clinical and laboratory variables showed no association.
  
  
  CONCLUSIONS
  Regardless of the mechanisms related to aspirin non-responsiveness, most patients enrolled in the present study also presented a reduced or minimal response to low-dose aspirin therapy, thereby indicating a clear variability related to aspirin effectiveness. Moreover, BMI appears to be independently associated to the reduction of urinary 11-dhTXB₂ concentrations in type 2 diabetic patients taking aspirin.
authors.affiliation: Department of Clinical and Toxicological Analysis-Faculty of Pharmacy-Federal University of Minas Gerais, Belo Horizonte, Brazil.
authors.forename: Lillian Harboe
authors.initials: LH
authors.lastname: Gonçalves
authors.forename: Luci Maria Sant'ana
authors.initials: LM
authors.lastname: Dusse
authors.forename: Ana Paula
authors.initials: AP
authors.lastname: Fernandes
authors.forename: Karina Braga
authors.initials: KB
authors.lastname: Gomes
authors.forename: Mirelle Oliveira
authors.initials: MO
authors.lastname: Sóter
authors.forename: Michelle Teodoro
authors.initials: MT
authors.lastname: Alves
authors.forename: Kathryna Fontana
authors.initials: KF
authors.lastname: Rodrigues
authors.forename: Fernanda Rocha
authors.initials: FR
authors.lastname: Freitas
authors.forename: Flavia
authors.initials: F
authors.lastname: Komatsuzaki
authors.forename: Marinez Oliveira
authors.initials: MO
authors.lastname: Sousa
authors.forename: Adriana Aparecida
authors.initials: AA
authors.lastname: Bosco
authors.forename: Gérson Antônio
authors.initials: GA
authors.lastname: Pianett
authors.forename: Maria das Graças
authors.initials: Md
authors.lastname: Carvalho
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine
chemical_list: D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D001241:Aspirin